Collaborative Network for Clinical Research on Immune Tolerance

The National Institute of Allergy and Infectious Diseases is preparing to support a collaborative network dedicated to advancing clinical research on immune tolerance, with the aim of deepening understanding of how immune tolerance is induced, maintained, and lost in humans. This initiative will focus on developing and testing tolerogenic interventions to prevent and treat immune-mediated conditions such as transplant rejection, autoimmune diseases, and allergic disorders like asthma. The program will conduct clinical trials across liver, kidney, and pancreatic islet transplantation, as well as allergic and autoimmune diseases, assessing the safety and efficacy of novel strategies while simultaneously investigating the underlying biological mechanisms of immune tolerance as an embedded component of these trials. Additionally, the network will work to create, refine, and validate immune monitoring assays capable of detecting and measuring tolerance states in patients, ensuring that clinical outcomes are supported by robust biomarker data. The collaboration will be funded under authorities established by Sections 301 and 405 of the Public Health Service Act, as amended, and regulated under Federal Regulations 42 CFR Part 52 and 2 CFR Part 200. This opportunity, titled Collaborative Network for Clinical Research on Immune Tolerance, was forecasted on June 24, 2026, and is being managed by the National Institutes of Health under the Department of Health and Human Services. Interested parties should direct inquiries to the Division of Allergy, Immunology and Transplantation at itn_um1@mail.nih.gov, and further details can be found through the grants.gov portal linked in the program information. The initiative is designed to foster coordinated, multidisciplinary research aimed at translating mechanistic insights into effective clinical therapies for conditions driven by dysregulated immune responses.